Elsevier

The Lancet

Volume 335, Issue 8700, 26 May 1990, Pages 1233-1235
The Lancet

MEDICAL SCIENCE
Cure of duodenal ulcer associated with eradication of Helicobacter pylori

https://doi.org/10.1016/0140-6736(90)91301-PGet rights and content

Abstract

50 patients with intractable duodenal ulcer were randomly assigned to 4 weeks of treatment with colloidal bismuth subcitrate (CBS) alone (26 patients) or with amoxicillin and metronidazole (24 patients). 5 patients (all on triple therapy) withdrew because of side-effects. In 17 of the 45 patients who completed the treatment, Helicobacter pylori was eradicated, and there was no ulcer relapse during the first 12 months of follow-up. The ulcer relapse rate was significantly higher (17 of 21 [89%]) among patients who remained positive for H pylori. 9 patients who remained positive for H pylori and had ulcer relapses within 6 months of treatment with CBS alone, were subsequently given triple therapy. 7 of the 9 showed H pylori eradication and no relapses within the next 12 months. The 2 patients still H pylori-positive after triple therapy had further ulcer relapses. H pylori eradication, without altering acid output, will become the mainstay of duodenal ulcer treatment because it cures the disease.

References (27)

  • Rl McIsaac et al.

    Ranitidine and cimetidine in the healing of duodenal ulcer: meta-analysis of comparative clinical trials

    Aliment Pharmacol Therap

    (1987)
  • Kg Wormsley

    Relapse of duodenal ulcer

    Br Med J

    (1986)
  • Ejs Boyd et al.

    Recurrent ulcer disease

  • Cited by (934)

    • We need to talk science

      2023, European Journal of Psychiatry
    • Surgery for Peptic Ulcer Disease

      2019, Shackelford's Surgery of the Alimentary Tract: 2 Volume Set
    • Helicobacter pylori infection

      2023, Nature Reviews Disease Primers
    View all citing articles on Scopus
    View full text